-
Roche And Biogen Idec (BIIB) Suspend Rheumatoid Arthritis Drug Program
Monday, March 8, 2010 - 9:07am | 119Swiss pharmaceutical company Roche Holding AG and Biogen Idec Inc (Nasdaq: BIIB) announced on Monday that safety concerns had caused them to suspend a program to treat rheumatoid arthritis with drug candidate ocrelizumab. The independent Data and Safety Monitoring Board had found that the potential...